BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hundie GB, Raj VS, GebreMichael D, Pas SD, Haagmans BL. Genetic diversity of hepatitis C virus in Ethiopia. PLoS One 2017;12:e0179064. [PMID: 28570623 DOI: 10.1371/journal.pone.0179064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Taye BW. A Path to Ending Hepatitis C in Ethiopia: A Phased Public Health Approach to Achieve Micro-Elimination. Am J Trop Med Hyg 2019;101:963-72. [PMID: 31516107 DOI: 10.4269/ajtmh.19-0295] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Gupta N, Mbituyumuremyi A, Kabahizi J, Ntaganda F, Muvunyi CM, Shumbusho F, Musabeyezu E, Mukabatsinda C, Ntirenganya C, Van Nuil JI, Kateera F, Camus G, Damascene MJ, Nsanzimana S, Mukherjee J, Grant PM. Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial. Lancet Gastroenterol Hepatol 2019;4:119-26. [PMID: 30552056 DOI: 10.1016/S2468-1253(18)30382-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
3 Camus G, Han B, Asselah T, Hsieh D, Dvory-Sobol H, Lu J, Svarovskaia E, Martin R, Parhy B, Miller MD, Brainard DM, Kersey K, Abergel A, Mo H. Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4. J Viral Hepat 2018;25:134-43. [PMID: 28984067 DOI: 10.1111/jvh.12795] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
4 Bhebhe L, Anderson M, Souda S, Choga WT, Zumbika E, Shaver ZM, Mbangiwa T, Phinius BB, Banda CC, Melamu P, Musonda RM, Essex M, Blackard JT, Moyo S, Gaseitsiwe S. Molecular characterization of hepatitis C virus in liver disease patients in Botswana: a retrospective cross-sectional study. BMC Infect Dis 2019;19:875. [PMID: 31640596 DOI: 10.1186/s12879-019-4514-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
5 Fourati S, Rodriguez C, Hézode C, Soulier A, Ruiz I, Poiteau L, Chevaliez S, Pawlotsky JM. Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r. Hepatology 2019;69:513-23. [PMID: 30125371 DOI: 10.1002/hep.30225] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 17.3] [Reference Citation Analysis]
6 Ebranati E, Mancon A, Airoldi M, Renica S, Shkjezi R, Dragusha P, Della Ventura C, Ciccaglione AR, Ciccozzi M, Bino S, Tanzi E, Micheli V, Riva E, Galli M, Zehender G. Time and Mode of Epidemic HCV-2 Subtypes Spreading in Europe: Phylodynamics in Italy and Albania. Diagnostics (Basel) 2021;11:327. [PMID: 33671355 DOI: 10.3390/diagnostics11020327] [Reference Citation Analysis]
7 Deress T, Million Y, Belachew T, Jemal M, Girma M. Seroprevalence of Hepatitis C Viral Infection in Ethiopia: A Systematic Review and Meta-Analysis. ScientificWorldJournal 2021;2021:8873389. [PMID: 33897305 DOI: 10.1155/2021/8873389] [Reference Citation Analysis]
8 Gupta N, Kateera F, Desalegn H, Ocama P, Njouom R, Lacombe K. Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action. Journal of Hepatology 2020;72:583-4. [DOI: 10.1016/j.jhep.2019.10.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bradshaw D, Mbisa JL, Geretti AM, Healy BJ, Cooke GS, Foster GR, Thomson EC, McLauchlan J, Agarwal K, Sabin C, Mutimer D, Moss P, Irving WL, Barnes E; Hepatitis C Trust, UK. Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. J Infect 2019;79:503-12. [PMID: 31629015 DOI: 10.1016/j.jinf.2019.10.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]